IL109807A - Pharmaceutical preparations containing esters of acids 3) and 3,4 d (dahmethylpricine 3) and 3,4 d (carboxyls and such new compounds - Google Patents

Pharmaceutical preparations containing esters of acids 3) and 3,4 d (dahmethylpricine 3) and 3,4 d (carboxyls and such new compounds

Info

Publication number: IL109807A
Authority: IL; Israel
Prior art keywords: hypericin; compound; total; carbon atoms; fewer carbon
Prior art date: 1993-05-27

Application number

IL10980794A

Other languages

English (en)

Hebrew (he)

Other versions

IL109807A0 (en

Inventor

Mazur Yehuda

Lavie Gad

Meruelo Daniel

Lavie David

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-27

Filing date

1994-05-27

Publication date

1998-12-06

1994-05-27 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1994-05-27 Priority to IL12313594A priority Critical patent/IL123135A/xx

1994-08-26 Publication of IL109807A0 publication Critical patent/IL109807A0/xx

1998-02-01 Priority to IL12313588A priority patent/IL123135A0/xx

1998-12-06 Publication of IL109807A publication Critical patent/IL109807A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 50
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
150000001733 carboxylic acid esters Chemical class 0.000 title description 4
230000000840 anti-viral effect Effects 0.000 claims abstract description 29
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 20
-1 2-(2-methoxyethoxy)ethyl Chemical group 0.000 claims abstract description 18
230000000798 anti-retroviral effect Effects 0.000 claims abstract description 13
125000000217 alkyl group Chemical group 0.000 claims abstract description 11
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 6
125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims abstract description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
239000001301 oxygen Substances 0.000 claims abstract description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims abstract 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 4
239000000203 mixture Substances 0.000 claims description 24
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 16
239000002502 liposome Substances 0.000 claims description 16
125000004432 carbon atom Chemical group C* 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
239000000934 spermatocidal agent Substances 0.000 claims description 2
SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 abstract description 53
229940005608 hypericin Drugs 0.000 abstract description 51
PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 abstract description 51
150000001990 dicarboxylic acid derivatives Chemical class 0.000 abstract description 3
BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 abstract 3
150000002762 monocarboxylic acid derivatives Chemical class 0.000 abstract 1
MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 71
241000700605 Viruses Species 0.000 description 28
ZJXVNNSMRGTDBI-UHFFFAOYSA-N Emodinsaeure Natural products C1=C(O)C=C2C(=O)C3=CC(C(=O)O)=CC(O)=C3C(=O)C2=C1O ZJXVNNSMRGTDBI-UHFFFAOYSA-N 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
CUUCCKPDUGAXQQ-UHFFFAOYSA-N Emodicacid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=CC=C2C(=O)O CUUCCKPDUGAXQQ-UHFFFAOYSA-N 0.000 description 11
RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 11
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
238000000034 method Methods 0.000 description 10
241001430294 unidentified retrovirus Species 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
230000000694 effects Effects 0.000 description 8
241000725303 Human immunodeficiency virus Species 0.000 description 7
150000004702 methyl esters Chemical class 0.000 description 7
238000006862 quantum yield reaction Methods 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000013060 biological fluid Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 6
ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 6
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
206010041660 Splenomegaly Diseases 0.000 description 5
150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
YLILOANQCQKPOD-UHFFFAOYSA-N protohypericin Chemical class C12=C(O)C=C(O)C(C(C3=C(O)C=C(C=C33)C)=O)=C2C3=C2C3=C1C(O)=CC(O)=C3C(=O)C1=C(O)C=C(C)C=C12 YLILOANQCQKPOD-UHFFFAOYSA-N 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
241001529936 Murinae Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
239000002245 particle Substances 0.000 description 4
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical class CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
102100034343 Integrase Human genes 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000000470 constituent Substances 0.000 description 3
125000004185 ester group Chemical group 0.000 description 3
235000003891 ferrous sulphate Nutrition 0.000 description 3
239000011790 ferrous sulphate Substances 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
CBOKHFLBNZMMAA-UHFFFAOYSA-N Emodin anthrone Natural products OC1=CC(O)=CC2=CC3=CC(C)=CC(O)=C3C(O)=C21 CBOKHFLBNZMMAA-UHFFFAOYSA-N 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000010836 blood and blood product Substances 0.000 description 2
229940125691 blood product Drugs 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
LAJSXCAVRQXZIO-UHFFFAOYSA-N emodin anthrone Chemical compound C1=C(O)C=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O LAJSXCAVRQXZIO-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ZKSVYBRJSMBDMV-UHFFFAOYSA-N 1,3-diphenyl-2-benzofuran Chemical compound C1=CC=CC=C1C1=C2C=CC=CC2=C(C=2C=CC=CC=2)O1 ZKSVYBRJSMBDMV-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
RZRJYURCNBXIST-UHFFFAOYSA-N 2-anthroic acid Chemical compound C1=CC=CC2=CC3=CC(C(=O)O)=CC=C3C=C21 RZRJYURCNBXIST-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000546188 Hypericum Species 0.000 description 1
235000017309 Hypericum perforatum Nutrition 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
208000036692 Sexual transmission of infection Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
125000006364 carbonyl oxy methylene group Chemical group [H]C([H])([*:2])OC([*:1])=O 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940124566 female contraceptive agent Drugs 0.000 description 1
229920002457 flexible plastic Polymers 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
244000309711 non-enveloped viruses Species 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Orthopedics, Nursing, And Contraception (AREA)

IL10980794A 1993-05-27 1994-05-27 Pharmaceutical preparations containing esters of acids 3) and 3,4 d (dahmethylpricine 3) and 3,4 d (carboxyls and such new compounds IL109807A (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
IL12313594A IL123135A (en)	1993-05-27	1994-05-27	Methods for reducing or eliminating viral or retroviral infectivity in vitro using 3-(and 3,4-di)demethylhypericin 3-(and 3,4-di) carboxylic acid esters
IL12313588A IL123135A0 (en)	1993-05-27	1998-02-01	Methods for reducing or eliminating viral or retroviral infectivity in vitro using 3- (and 3,4-di) demethylhypericin-3- (and 3,4-di) carboxylic acid esters

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/068,379 US6576784B1 (en)	1993-05-27	1993-05-27	Antiviral agents

Publications (2)

Publication Number	Publication Date
IL109807A0 IL109807A0 (en)	1994-08-26
IL109807A true IL109807A (en)	1998-12-06

Family

ID=22082194

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10980794A IL109807A (en)	1993-05-27	1994-05-27	Pharmaceutical preparations containing esters of acids 3) and 3,4 d (dahmethylpricine 3) and 3,4 d (carboxyls and such new compounds

Country Status (12)

Country	Link
US (1)	US6576784B1 (da)
EP (1)	EP0702669B1 (da)
JP (1)	JPH08510753A (da)
AT (1)	ATE168985T1 (da)
AU (1)	AU689120B2 (da)
CA (1)	CA2163793C (da)
DE (1)	DE69412095T2 (da)
DK (1)	DK0702669T3 (da)
ES (1)	ES2122303T3 (da)
GR (1)	GR3027710T3 (da)
IL (1)	IL109807A (da)
WO (1)	WO1994027952A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL121440A0 (en)	1997-07-31	1998-01-04	Yeda Res & Dev	The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
EP1094712A4 (en) *	1998-07-09	2004-09-08	Cv Technologies Inc	HYPERICIN AND HYPERICUM EXTRACT: AGENTS THAT BLOCK TYPE C CALCIUM CHANNELS AND THEIR USE AS THERAPEUTIC AGENTS DIRECTED AGAINST TYPE T CALCIUM CHANNEL
DK175561B1 (da) *	1999-01-11	2004-12-06	Lego As	Legetöjsbyggesæt med system til overföring af energi mellem byggeelementer
EP1040825A1 (en) *	1999-03-11	2000-10-04	K.U. Leuven Research & Development	Means for diagnosing bladder carcinoma
US7195783B2 (en)	1999-07-09	2007-03-27	Fx Life Sciences International Gmbh	Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
US7037534B2 (en) *	2001-10-24	2006-05-02	Aphios Corporation	Inactivation of viral infections agents by chemiluminescence activated light-sensitive compounds
US20080199458A1 (en) *	2007-01-19	2008-08-21	Jian-Er Lin	Influenza prevention and treatment composition
RU2719582C1 (ru) *	2016-03-01	2020-04-21	Солидженикс, Инк.	Системы и способы для получения синтетического гиперицина

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL93682A (en) *	1989-03-16	1996-06-18	Yeda Res & Dev	Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
AU3056492A (en)	1991-11-01	1993-06-07	New York University	Hypericin compositions for treating t-cell mediated diseases

1993
- 1993-05-27 US US08/068,379 patent/US6576784B1/en not_active Expired - Lifetime
1994
- 1994-05-27 DE DE69412095T patent/DE69412095T2/de not_active Expired - Fee Related
- 1994-05-27 CA CA002163793A patent/CA2163793C/en not_active Expired - Fee Related
- 1994-05-27 IL IL10980794A patent/IL109807A/en not_active IP Right Cessation
- 1994-05-27 AT AT94921214T patent/ATE168985T1/de not_active IP Right Cessation
- 1994-05-27 EP EP94921214A patent/EP0702669B1/en not_active Expired - Lifetime
- 1994-05-27 DK DK94921214T patent/DK0702669T3/da active
- 1994-05-27 JP JP7500974A patent/JPH08510753A/ja active Pending
- 1994-05-27 WO PCT/US1994/005975 patent/WO1994027952A1/en not_active Ceased
- 1994-05-27 ES ES94921214T patent/ES2122303T3/es not_active Expired - Lifetime
- 1994-05-27 AU AU72023/94A patent/AU689120B2/en not_active Ceased
1998
- 1998-08-20 GR GR980401887T patent/GR3027710T3/el unknown

Also Published As

Publication number	Publication date
ATE168985T1 (de)	1998-08-15
DK0702669T3 (da)	1998-11-09
DE69412095T2 (de)	1998-12-03
US6576784B1 (en)	2003-06-10
GR3027710T3 (en)	1998-11-30
DE69412095D1 (de)	1998-09-03
ES2122303T3 (es)	1998-12-16
CA2163793A1 (en)	1994-12-08
AU689120B2 (en)	1998-03-26
EP0702669A4 (en)	1996-01-29
CA2163793C (en)	2007-04-17
IL109807A0 (en)	1994-08-26
EP0702669B1 (en)	1998-07-29
JPH08510753A (ja)	1996-11-12
EP0702669A1 (en)	1996-03-27
WO1994027952A1 (en)	1994-12-08
AU7202394A (en)	1994-12-20

Legal Events

Date	Code	Title
1999-06-20	FF	Patent granted
1999-10-28	KB	Patent renewed
2004-07-25	KB	Patent renewed
2008-08-10	KB	Patent renewed
2013-02-03	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
Tsai et al.	1995	Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine
US4513008A (en)	1985-04-23	Virucidal compositions and therapy
US5665762A (en)	1997-09-09	Decontaminating clinical samples
US6002029A (en)	1999-12-14	Antiviral prodrugs
Degar et al.	1992	Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating
US4602037A (en)	1986-07-22	Xanthates and antiviral use thereof
WO1990004918A2 (en)	1990-05-17	Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
EP0702669B1 (en)	1998-07-29	Novel antiviral agents
UA78709C2 (en)	2007-04-25	Spiro or dispiro-1,2,4-trioxolane as antimalarial agents, pharmaceutical composition, method of production
CA2001898A1 (en)	1990-04-30	Inhibition of human retroviruses
CA2083945C (en)	1995-02-07	An antiviral composition
Chanh et al.	1994	Inhibition of retrovirus-induced syncytium formation by photoproducts of a brominated 1, 8-naphthalimide compound
CA2029863C (en)	2001-10-30	Compositions and methods for treating viral infections
NZ232929A (en)	1991-07-26	Tungsten compounds containing a lanthanide ion and their use in antiviral compositions
Fujiwara et al.	1996	Ingenol derivatives are highly potent and selective inhibitors of HIV replication in vitro
WO1994020090A1 (en)	1994-09-15	Decontaminating clinical samples
NZ187243A (en)	1984-07-31	Sesquiterpenes from culturing a stachybotrys genus or memmoniella simplex strain microorganism
AU671827B2 (en)	1996-09-12	Calanolide antiviral compounds, compositions and uses thereof
US5079239A (en)	1992-01-07	Sterol disulfates and methods of use
Hudson et al.	1993	Light‐mediated activities of thiarubrines against human immunodeficiency virus
Kinchington et al.	1993	Lithium γ‐linolenate‐induced cytotoxicity against cells chronically infected with HIV‐1
WO2016190331A1 (ja)	2016-12-01	Ｈｉｖ感染阻害剤
Lee et al.	1992	Tannins and Related Compounds as Anti-HIV Agents 1
AU3720593A (en)	1993-09-03	Ion pairs of hypericin compounds having antiviral activity
PT96331A (pt)	1991-10-15	Processo de preparacao de composicoes farmaceuticas, a base de floroglucinol e de seus derivados